Randomized phase 2 study of investigational aurora A kinase (AAK) inhibitor alisertib (MLN8237) + paclitaxel (P) vs placebo + P as second line therapy for small-cell lung cancer (SCLC)

Saved in:
Bibliographic Details
Published inAnnals of oncology Vol. 27; p. vi493
Main Authors Owonikoko, T.K., Nackaerts, K., Csoszi, T., Ostoros, G., Baik, C., Mark, Z., Sheldon-Waniga, E., Huebner, D., Leonard, E.J., Spigel, D.R.
Format Journal Article
LanguageEnglish
Published Elsevier Ltd 01.10.2016
Online AccessGet full text

Cover

More Information
ISSN:0923-7534
1569-8041
DOI:10.1093/annonc/mdw389.01